-
-
Identification of an EML4-ALK rearrangement reveals optimal new treatment for lung cancer
Learn more
-
-
-
Identification of a PIK3CA mutation explains targeted therapy resistance and offers a new clinical trial option for lung cancer
Learn more
-
-
-
KRAS mutation indicates colorectal cancer is unlikely to respond to available therapies, but suggests an alternative therapeutic strategy
Learn more
-
-
-
Rebiopsy reveals valuable new genomic information for treating gastrointestinal stromal tumor (GIST)
Learn more
-
-
-
Genomic subtyping opens a clinical trial option for metastatic endometrial cancer
Learn more
-
-
-
BRAF mutation in melanoma opens an option for targeted initial therapy
Learn more
-
Foundation Medicine is a cancer diagnostics company at the forefront of bringing comprehensive genomic analysis to routine cancer care. Foundation Medicine's clinical laboratory services help physicians and their patients tailor therapy based on each tumor's molecular subtype.
Calendar of Events
- February 8, 2012 | M.I.T Enterprise Forum
- February 15-18, 2012 | Advances in Genome Biology and Technology Meeting
- March 31 - April 4, 2012 | AACR 103rd Annual Meeting
Press ReleaseS
- January 10, 2012 | Foundation Medicine Announces Collaboration with Sanofi